Riskpilot← Back to searchSign inGet full accessLäkarkonsult Syd AB
ABActiveOrg 5591724132Vegagatan 15Hospital activities · NACE 8610Est. 20180 employees
Revenue 2025
SEK 27K
-82% vs 2024
EBITDA margin
-201.2%
-160% vs 2024
Equity ratio
34.8%
Financial strength
Net profit 2025
SEK -55K
-178% vs 2024
| Revenue | SEK 27K | -82% |
| EBITDA | SEK -55K | -160% |
| Net profit | SEK -55K | -178% |
| Total assets | SEK 45K | -74% |
| Equity | SEK 16K | -85% |
| Employees | 0 | — |
Legal name
Läkarkonsult Syd AB
Org number
5591724132
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
21 september 2018
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva verksamhet inom hälso- och sjukvård, naturvetenskaplig forskning, utbildning, konsultation och därmed förenlig verksamhet. Bolaget skall även bedriva handel med och förvaltning av värdepapper. Samt åt förvärv och utveckling av båtar och fastigheter och därmed förenlig verksamhet.
Address
Vegagatan 15
Email
sand_adam@outlook.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 142 | 116 | 80 | 151 | 27 |
| Staff expenses | — | −20 | — | −23 | −15 |
| EBITDA | 66 | 52 | 15 | 91 | −55 |
| Depreciation & amort. | −0 | — | −0 | — | — |
| EBIT | 66 | 52 | 15 | 91 | −55 |
| Net financials | — | −1 | — | 0 | 0 |
| Profit before tax | 66 | 51 | 15 | 92 | −55 |
| Tax | −17 | −13 | −5 | −21 | — |
| Net profit | 49 | 38 | 10 | 70 | −55 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 136 | 131 | 84 | 171 | 45 |
| Equity | 74 | 63 | 35 | 106 | 16 |
| Long-term debt | 0 | — | 0 | — | — |
| Short-term debt | 61 | 68 | 49 | 66 | 30 |
| Total debt | 61 | 68 | 49 | 66 | 30 |
EBITDA margin
-201.2%
This company
15.8%
Market median
-1373% vs market
20212025
Equity ratio
34.8%
This company
38.2%
Market median
+9% vs market
20212025
Return on equity
-348.9%
This company
18.4%
Market median
-1996% vs market
20212025
Net profit margin
-200.8%
This company
8.1%
Market median
-2579% vs market
20212025
Asset turnover
0.60×
This company
1.12×
Market median
-46% vs market
20212025
Debt / equity
1.88×
This company
0.62×
Market median
-203% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Chairman | 2022 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Läkarkonsult Syd AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cecilia Margareta Luts | Board of Directors | 0 companies |
| Philip Adam Sand | Chairman | 0 companies |
| Gert Ove Sonesson | Deputy Board Member | 0 companies |